Entera Bio (ENTX) Change in Cash (2021 - 2026)

Entera Bio (ENTX) has 6 years of Change in Cash data on file, last reported at -$3.0 million in Q1 2026.

• Quarterly Change in Cash fell 124.82% year-over-year to -$3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.7 million (down 176.13% YoY) and the FY2025 annual result came in at $6.2 million, up 364.26% from the prior year.
• Change in Cash retreated to -$3.0 million in Q1 2026, from -$1.7 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $11.9 million in Q1 2025 to a low of -$4.8 million in Q1 2022.
• A 5-year average of -$763941.2 and a median of -$1.7 million in 2025 frame the typical range for Change in Cash.
• The widest YoY moves for Change in Cash: up 750.93% in 2025, down 1337.82% in 2025.
• Tracing ENTX's Change in Cash over 5 years: stood at -$2.0 million in 2022, then soared by 269.27% to $3.4 million in 2023, then tumbled by 48.75% to $1.7 million in 2024, then slumped by 198.57% to -$1.7 million in 2025, then sank by 71.89% to -$3.0 million in 2026.
• The last three Change in Cash figures came in at -$3.0 million (Q1 2026), -$1.7 million (Q4 2025), and -$2.3 million (Q3 2025), per Business Quant data.